American College of Rheumatology response (ACR20, ACR50, and ACR70) and European League Against Rheumatism (EULAR) response (at least moderate and good) at weeks 2 and 26 (observed values)
| Response | Adalimumab sc | Placebo (n = 110) | |||
|---|---|---|---|---|---|
| 20 mg | 40 mg | ||||
| Every other week (n = 106) | Weekly (n = 112) | Every other week (n = 113) | Weekly (n = 103) | ||
| Results are shown as No (%). | |||||
| Comparison v placebo (Pearson’s χ2 test): *p⩽0.05; †p⩽0.01; ‡p⩽0.001. | |||||
| §No EULAR response was defined as a decrease in DAS28 of ⩽0.6 or a decrease >0.6 but ⩽1.2 with an attained DAS28 of >5.1. A good EULAR response was defined as a decrease in DAS28 of >1.2 and an attained DAS28 of ⩽3.2. Remaining patients were classified as EULAR moderate responders. | |||||
| sc, subcutaneous; DAS, disease activity score. | |||||
| ACR20 | |||||
| Week 2 | 40 (37.7)‡ | 43 (38.4)‡ | 40 (35.4)‡ | 34 (33.0)‡ | 8 (7.3) |
| Week 26 | 38 (35.8)† | 44 (39.3)‡ | 52 (46.0)‡ | 55 (53.4)‡ | 21 (19.1) |
| ACR50 | |||||
| Week 2 | 5 (4.7)* | 7 (6.3)† | 11 (9.7)‡ | 11 (10.7)‡ | 0 (0.0) |
| Week 26 | 20 (18.9)* | 23 (20.5)† | 25 (22.1)† | 36 (35.0)‡ | 9 (8.2) |
| ACR70 | |||||
| Week 2 | 1 (0.9) | 0 (0.0) | 4 (3.5)* | 2 (1.9) | 0 (0.0) |
| Week 26 | 9 (8.5)* | 11 (9.8)* | 14 (12.4)† | 19 (18.4)‡ | 2 (1.8) |
| EULAR: at least moderate § | |||||
| Week 2 | 51 (48.1)‡ | 54 (48.2)‡ | 57 (50.4)‡ | 50 (48.5)‡ | 16 (14.5) |
| Week 26 | 44 (41.5)* | 54 (48.2)‡ | 63 (55.8)‡ | 65 (63.1)‡ | 29 (26.4) |
| EULAR: good§ | |||||
| Week 2 | 2 (1.9) | 1 (0.9) | 4 (3.5)* | 1 (1.0) | 0 (0.0) |
| Week 26 | 7 (6.6) | 11 (9.8) | 10 (8.8) | 14 (13.6)† | 4 (3.6) |